Akero Therapeutics (AKRO) said late Tuesday it priced an upsized public offering of about 5.3 million shares at $48 each and pre-funded warrants to purchase about 2 million shares at $47.9999 per warrant.
The company anticipates gross proceeds of $350 million.
Underwriters have a 30-day option to acquire up to about 1.1 million additional shares, the company said.
The offering is expected to close on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。